Spartha Medical and the EIC Accelerator: Coatings in Receivership
Infections picked up in hospital, including on implants and surgical wounds, are the problem Spartha Medical was founded to tackle. Spartha Medical, a 2019 spin-off from France's national health research institute INSERM in Strasbourg, develops very thin biopolymer coatings that release antimicrobial and anti-inflammatory agents, for medical devices, wounds and textiles.
The European Innovation Council granted €2,389,625 towards a €3.41 million project that built coating devices and prototypes and prepared clinical trials. None had started by the project's end in July 2025. On 31 August 2026 a French court opened a receivership (redressement judiciaire), dating Spartha's insolvency to 1 February 2026, according to the official BODACC notice.
Company file
- Legal entity
- Spartha Medical SAS, SIREN 877489203, Strasbourg, France
- Registered
- October 2019; INSERM UMR1121 spin-off
- CEO
- Nihal Engin Vrana, co-founder
- Products
- Antimicrobial coatings; spray device; protect|ION (Class IIb, in development)
- Accounts 2024
- Revenue €0; net result €241,862
- Status
- Receivership (redressement judiciaire) since 31 August 2026
- EIC project
- SPARTHACUS, 1 Aug 2022 to 31 Jul 2025
- EIC funding
- Blended finance
Where Spartha Medical Stands Today
The BODACC, France's official gazette of company notices, published on 4 September 2026 a judgment of 31 August 2026 opening a receivership for Spartha Medical, with an administrator appointed. In French law, receivership gives a company time to propose a recovery plan under court supervision; if that fails, it moves to liquidation. The court set the date Spartha stopped paying its debts as 1 February 2026. Its website still carries a page about investing through the crowdfunding platform WiSEED; we could not tell from it whether any offer is open. Its 2024 accounts, in the French register data, show no revenue and a net result of €241,862.
The Technology: Very Thin Coatings
Spartha's coatings come from research at INSERM that, according to its website, discovered their antimicrobial properties in 2013. They are built from layers of biopolymers that release infection-fighting molecules gradually and then degrade. In a Eurostars project launched in 2025, Spartha is applying its coating to a sleeve that wraps around pacemakers during implantation.
"We aim to show how you can realize big differences with very thin coatings, just like the capacity of one person to change the history."
Nihal Engin Vrana, CEO, Spartha Medical, on SPARTHACUSWhat the EIC Project Promised, and What CORDIS Shows
The EIC project
The EU paid 70% of a €3.41M project
SPARTHACUS ran from August 2022 to July 2025. The award was blended finance.
CORDIS project 190184905. Values in € millions.
SPARTHACUS promised "innovative multifunctional and smart coatings to prevent medical device related infections". The CORDIS report lists a handheld spray device that applies antimicrobial membranes to tissue, validated in four preclinical models, an antimicrobial hydrogel, an industrial dipping robot prototype, and protect|ION, a device planned as Class IIb, whose "1st prototype tested with strong antimicrobial activity". It reports a production chain, a quality system aligned with ISO 13485, an FDA pre-submission, seven patent filings and trial protocols with Strasbourg hospitals for colorectal surgery and chronic wounds, but no trial under way.
The output
What SPARTHACUS reports it produced
Company-reported outputs of the EIC project: patent filings, preclinical models validating the spray device, high-impact publications and clinical trials started.
CORDIS project 190184905 results.
- Coatings and devicesDeliveredSpray device, hydrogel, protect|ION prototype.
- Manufacturing and qualityDeliveredProduction chain; ISO 13485-aligned.
- Clinical trialsMissedProtocols only.
- A solvent companyMissedReceivership, August 2026.
What Has Happened Since the Award
The record
From INSERM spin-off to receivership
Spartha developed its coatings and devices to the edge of clinical trials under the EIC project, then entered receivership in August 2026.
- Oct 2019Company registeredINSERM spin-off, Strasbourg
- Oct 2021EIC Accelerator cut-offSPARTHACUS: smart coatings against device infections
- Aug 2022EIC project startsCoatings, spray device, protect|ION€2.39M grant
- Apr 20254D-EASLEEEurostars project for an antimicrobial pacemaker sleeve
- Jul 2025EIC project endsTrial protocols ready; 7 patent filings
- Feb 2026Payments stopInsolvency date set by the court
- Aug 2026ReceivershipRedressement judiciaire opened; administrator appointedInsolvent
Spartha Medical, CORDIS and BODACC.
The Money
The award was blended finance; we found no EIC Fund investment. Spartha's website names support from the technology transfer office SATT Conectus and research tax credits, and a €1.4 million funding round. It has since sought money through WiSEED. It recorded no revenue in 2024.
What cannot be checked
How much the WiSEED campaign raised, what Spartha owes, whether a recovery plan or buyer exists and whether the EIC took equity are not public.
Why Europe Should Care
Preventing infections on medical devices would reduce hospital complications. Spartha turned French public research into products ready for trials with EU money, and then entered receivership without testing them in patients. A recovery plan could still keep the technology alive.
What the project promised
Smart, multifunctional coatings to prevent infections related to medical devices.
What the record shows
Prototypes, patents and trial protocols; no trial started, no revenue and a receivership.
The Verdict
Ready for the clinic, then receivership
SPARTHACUS produced much of what it promised in the lab and on the production line. But it did not reach patients, and a year after the project ended Spartha was in receivership. The outcome now depends on whether the court-supervised process finds a way to continue.
Spartha Medical has not been asked for comment for this article. It is based entirely on company statements, EU project data and French official notices, linked throughout.
Industry
HealthMedical devices
- Focus
- Infection control devices
- Technologies
- Biopolymers
- Controlled release
- Surface engineering
- Keywords
- Antimicrobial coatings
- Hospital-acquired infections
- Implant infections
- Wound care
- Pacemakers
- Surface coatings